Premium
MiR‐199b‐5p targets HER2 in breast cancer cells
Author(s) -
Fang Chen,
Zhao Yu,
Guo Baoyu
Publication year - 2013
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.24487
Subject(s) - microrna , trastuzumab , cancer research , breast cancer , cancer , protein kinase b , metastasis , medicine , signal transduction , gene , biology , microbiology and biotechnology , genetics
HER2 (ErbB2) has been reported to be overexpressed in 20–30% of breast cancer and confers poor survival because of high proliferation and metastasis rates. MicroRNAs are small noncoding RNAs that are responsible for the post‐transcriptional regulation of target genes. We found miR‐199b‐5p inhibited HER2 expression by direct targeting its 3′‐untranslated region (3′UTR) in breast cancer cells. In addition, miR‐199b‐5p inhibited HER2 downstream signaling by ERK1/2 and AKT pathways in breast cancer cells. Besides, transwell migration, wound healing, and clonogenicity were obviously inhibited by overexpression of miR‐199b‐5p in HER2‐positive breast cancer cells. We also found that miR‐199b‐5p could enhance the suppression of trastuzumab on cell migration and clonogenicity. These results suggest that miR‐199b‐5p may have the potential to be a novel important alternative therapeutic target for HER2‐positive breast cancer. J. Cell. Biochem. 114: 1457–1463, 2013. © 2013 Wiley Periodicals, Inc.